Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment

Background The clinical behavior and optimal treatment of relapsing and recurrent peritonitis episodes in patients undergoing long-term peritoneal dialysis are poorly understood. Study Design Retrospective study over 14 years. Setting & Participants University dialysis unit; 157 relapsing episod...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of kidney diseases 2009-10, Vol.54 (4), p.702-710
Hauptverfasser: Szeto, Cheuk-Chun, MD, FRCP, Kwan, Bonnie Ching-Ha, MBBS, MCP(UK), Chow, Kai-Ming, MBChB, MRCP(UK), Law, Man-Ching, BN, RN, Pang, Wing-Fai, MBChB, MRCP(UK), Chung, Kwok-Yi, MBChB, MRCP(UK), Leung, Chi-Bon, MBChB, FRCP(Edin), Li, Philip Kam-Tao, MD, FRCP
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 710
container_issue 4
container_start_page 702
container_title American journal of kidney diseases
container_volume 54
creator Szeto, Cheuk-Chun, MD, FRCP
Kwan, Bonnie Ching-Ha, MBBS, MCP(UK)
Chow, Kai-Ming, MBChB, MRCP(UK)
Law, Man-Ching, BN, RN
Pang, Wing-Fai, MBChB, MRCP(UK)
Chung, Kwok-Yi, MBChB, MRCP(UK)
Leung, Chi-Bon, MBChB, FRCP(Edin)
Li, Philip Kam-Tao, MD, FRCP
description Background The clinical behavior and optimal treatment of relapsing and recurrent peritonitis episodes in patients undergoing long-term peritoneal dialysis are poorly understood. Study Design Retrospective study over 14 years. Setting & Participants University dialysis unit; 157 relapsing episodes (same organism or culture-negative episode occurring within 4 weeks of completion of therapy for a prior episode), 125 recurrent episodes (different organism, occurs within 4 weeks of completion of therapy for a prior episode), and 764 control episodes (first peritonitis episode without relapse or recurrence). Predictors Exit-site infection, empirical antibiotics. Outcome Measures Primary response (resolution of abdominal pain, clearing of dialysate, and peritoneal dialysis effluent neutrophil count < 100 cells/mL after 10 days of antibiotic therapy), complete cure (resolution by using antibiotics without relapse/recurrence), catheter removal (for any cause while on antibiotic therapy), and mortality. Results Compared with the control group, more relapsing episodes were caused by Pseudomonas species (16.6% versus 9.4%) and were culture negative (29.9% versus 16.4%); recurrent infections commonly were caused by Enterococcus species (3.2% versus 1.2%) or other Gram-negative organisms (27.2% versus 11.1%) or had mixed bacterial growth (17.6% versus 12.7%). There were significant differences in primary response, complete cure, and mortality rates among groups ( P < 0.001 for all comparisons). Compared with the control and relapsing groups, post hoc analysis showed that the recurrent group had a significantly lower primary response rate (86.4%, 88.5%, and 71.2%, respectively), lower complete cure rate (72.3%, 62.4%, and 42.4%, respectively), and higher mortality rate (7.7%, 7.0%, and 20.8%, respectively). Limitations Retrospective analysis. Conclusion Relapsing and recurrent peritonitis episodes are caused by different spectra of bacteria and probably represent 2 distinct clinical entities. Recurrent peritonitis episodes had a worse prognosis than relapsing ones.
doi_str_mv 10.1053/j.ajkd.2009.04.032
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67671133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0272638609007689</els_id><sourcerecordid>67671133</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-55e5d5dfc34191b93a217d2492ac8c2a31214220f82e7ee734d9dfa4d1c842473</originalsourceid><addsrcrecordid>eNp9kU2L1TAUhoMoznX0D7iQbnTXmo-maUUEuTgqDIxcx3XIJKdDOm16zUkH5t-bcssILlydzfO-5_AcQl4zWjEqxfuhMsOdqzilXUXrigr-hOyY5KJsWtE-JTvKFS8b0TZn5AXiQDMomuY5OWOdVEpIviOHA9glRgipMMEVBxjNEX24LX5A9GkOPnn8UOzNgib5eyiu4q0JHifccDzOAaFIc3EdwaQpF70kz3ozIrza5jn5dfHlev-tvLz6-n3_-bK0kspUSgnSSddbUbOO3XTCcKYcrztubGu5EYyzmnPatxwUgBK161xvasdsW_NaiXPy7tR7jPPvBTDpyaOFcTQB5gV1oxrFmBAZ5CfQxhkxQq-P0U8mPmhG9WpSD3o1qVeTmtY6m8yhN1v7cjOB-xvZ1GXg7QYYtGbsownW4yPHWddKzmTmPp44yC7uPUSN1kOw4HwEm7Sb_f_v-PRP3I4--LzxDh4Ah3mJIVvWTCPXVP9cf76-nHaUqqbtxB9DeKY2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67671133</pqid></control><display><type>article</type><title>Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Szeto, Cheuk-Chun, MD, FRCP ; Kwan, Bonnie Ching-Ha, MBBS, MCP(UK) ; Chow, Kai-Ming, MBChB, MRCP(UK) ; Law, Man-Ching, BN, RN ; Pang, Wing-Fai, MBChB, MRCP(UK) ; Chung, Kwok-Yi, MBChB, MRCP(UK) ; Leung, Chi-Bon, MBChB, FRCP(Edin) ; Li, Philip Kam-Tao, MD, FRCP</creator><creatorcontrib>Szeto, Cheuk-Chun, MD, FRCP ; Kwan, Bonnie Ching-Ha, MBBS, MCP(UK) ; Chow, Kai-Ming, MBChB, MRCP(UK) ; Law, Man-Ching, BN, RN ; Pang, Wing-Fai, MBChB, MRCP(UK) ; Chung, Kwok-Yi, MBChB, MRCP(UK) ; Leung, Chi-Bon, MBChB, FRCP(Edin) ; Li, Philip Kam-Tao, MD, FRCP</creatorcontrib><description>Background The clinical behavior and optimal treatment of relapsing and recurrent peritonitis episodes in patients undergoing long-term peritoneal dialysis are poorly understood. Study Design Retrospective study over 14 years. Setting &amp; Participants University dialysis unit; 157 relapsing episodes (same organism or culture-negative episode occurring within 4 weeks of completion of therapy for a prior episode), 125 recurrent episodes (different organism, occurs within 4 weeks of completion of therapy for a prior episode), and 764 control episodes (first peritonitis episode without relapse or recurrence). Predictors Exit-site infection, empirical antibiotics. Outcome Measures Primary response (resolution of abdominal pain, clearing of dialysate, and peritoneal dialysis effluent neutrophil count &lt; 100 cells/mL after 10 days of antibiotic therapy), complete cure (resolution by using antibiotics without relapse/recurrence), catheter removal (for any cause while on antibiotic therapy), and mortality. Results Compared with the control group, more relapsing episodes were caused by Pseudomonas species (16.6% versus 9.4%) and were culture negative (29.9% versus 16.4%); recurrent infections commonly were caused by Enterococcus species (3.2% versus 1.2%) or other Gram-negative organisms (27.2% versus 11.1%) or had mixed bacterial growth (17.6% versus 12.7%). There were significant differences in primary response, complete cure, and mortality rates among groups ( P &lt; 0.001 for all comparisons). Compared with the control and relapsing groups, post hoc analysis showed that the recurrent group had a significantly lower primary response rate (86.4%, 88.5%, and 71.2%, respectively), lower complete cure rate (72.3%, 62.4%, and 42.4%, respectively), and higher mortality rate (7.7%, 7.0%, and 20.8%, respectively). Limitations Retrospective analysis. Conclusion Relapsing and recurrent peritonitis episodes are caused by different spectra of bacteria and probably represent 2 distinct clinical entities. Recurrent peritonitis episodes had a worse prognosis than relapsing ones.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2009.04.032</identifier><identifier>PMID: 19577352</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Abdomen ; Adult ; Aged ; Anti-Bacterial Agents - therapeutic use ; antibiotics ; Biological and medical sciences ; Cefazolin - therapeutic use ; Ceftazidime - therapeutic use ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Gentamicins - metabolism ; Gentamicins - therapeutic use ; Gram-Negative Bacterial Infections - drug therapy ; Gram-Negative Bacterial Infections - microbiology ; Gram-Positive Bacterial Infections - drug therapy ; Gram-Positive Bacterial Infections - microbiology ; Humans ; Logistic Models ; Male ; Medical sciences ; Middle Aged ; Nephrology ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Netilmicin - therapeutic use ; nosocomial infection ; Other diseases. Semiology ; Peritoneal Dialysis - adverse effects ; Peritonitis - drug therapy ; Peritonitis - etiology ; Peritonitis - microbiology ; Prognosis ; Recurrence ; Renal failure ; Retrospective Studies ; Risk Factors ; Vancomycin - therapeutic use</subject><ispartof>American journal of kidney diseases, 2009-10, Vol.54 (4), p.702-710</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2009 National Kidney Foundation, Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-55e5d5dfc34191b93a217d2492ac8c2a31214220f82e7ee734d9dfa4d1c842473</citedby><cites>FETCH-LOGICAL-c505t-55e5d5dfc34191b93a217d2492ac8c2a31214220f82e7ee734d9dfa4d1c842473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0272638609007689$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21985215$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19577352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szeto, Cheuk-Chun, MD, FRCP</creatorcontrib><creatorcontrib>Kwan, Bonnie Ching-Ha, MBBS, MCP(UK)</creatorcontrib><creatorcontrib>Chow, Kai-Ming, MBChB, MRCP(UK)</creatorcontrib><creatorcontrib>Law, Man-Ching, BN, RN</creatorcontrib><creatorcontrib>Pang, Wing-Fai, MBChB, MRCP(UK)</creatorcontrib><creatorcontrib>Chung, Kwok-Yi, MBChB, MRCP(UK)</creatorcontrib><creatorcontrib>Leung, Chi-Bon, MBChB, FRCP(Edin)</creatorcontrib><creatorcontrib>Li, Philip Kam-Tao, MD, FRCP</creatorcontrib><title>Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>Background The clinical behavior and optimal treatment of relapsing and recurrent peritonitis episodes in patients undergoing long-term peritoneal dialysis are poorly understood. Study Design Retrospective study over 14 years. Setting &amp; Participants University dialysis unit; 157 relapsing episodes (same organism or culture-negative episode occurring within 4 weeks of completion of therapy for a prior episode), 125 recurrent episodes (different organism, occurs within 4 weeks of completion of therapy for a prior episode), and 764 control episodes (first peritonitis episode without relapse or recurrence). Predictors Exit-site infection, empirical antibiotics. Outcome Measures Primary response (resolution of abdominal pain, clearing of dialysate, and peritoneal dialysis effluent neutrophil count &lt; 100 cells/mL after 10 days of antibiotic therapy), complete cure (resolution by using antibiotics without relapse/recurrence), catheter removal (for any cause while on antibiotic therapy), and mortality. Results Compared with the control group, more relapsing episodes were caused by Pseudomonas species (16.6% versus 9.4%) and were culture negative (29.9% versus 16.4%); recurrent infections commonly were caused by Enterococcus species (3.2% versus 1.2%) or other Gram-negative organisms (27.2% versus 11.1%) or had mixed bacterial growth (17.6% versus 12.7%). There were significant differences in primary response, complete cure, and mortality rates among groups ( P &lt; 0.001 for all comparisons). Compared with the control and relapsing groups, post hoc analysis showed that the recurrent group had a significantly lower primary response rate (86.4%, 88.5%, and 71.2%, respectively), lower complete cure rate (72.3%, 62.4%, and 42.4%, respectively), and higher mortality rate (7.7%, 7.0%, and 20.8%, respectively). Limitations Retrospective analysis. Conclusion Relapsing and recurrent peritonitis episodes are caused by different spectra of bacteria and probably represent 2 distinct clinical entities. Recurrent peritonitis episodes had a worse prognosis than relapsing ones.</description><subject>Abdomen</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>antibiotics</subject><subject>Biological and medical sciences</subject><subject>Cefazolin - therapeutic use</subject><subject>Ceftazidime - therapeutic use</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gentamicins - metabolism</subject><subject>Gentamicins - therapeutic use</subject><subject>Gram-Negative Bacterial Infections - drug therapy</subject><subject>Gram-Negative Bacterial Infections - microbiology</subject><subject>Gram-Positive Bacterial Infections - drug therapy</subject><subject>Gram-Positive Bacterial Infections - microbiology</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Netilmicin - therapeutic use</subject><subject>nosocomial infection</subject><subject>Other diseases. Semiology</subject><subject>Peritoneal Dialysis - adverse effects</subject><subject>Peritonitis - drug therapy</subject><subject>Peritonitis - etiology</subject><subject>Peritonitis - microbiology</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Renal failure</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Vancomycin - therapeutic use</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2L1TAUhoMoznX0D7iQbnTXmo-maUUEuTgqDIxcx3XIJKdDOm16zUkH5t-bcssILlydzfO-5_AcQl4zWjEqxfuhMsOdqzilXUXrigr-hOyY5KJsWtE-JTvKFS8b0TZn5AXiQDMomuY5OWOdVEpIviOHA9glRgipMMEVBxjNEX24LX5A9GkOPnn8UOzNgib5eyiu4q0JHifccDzOAaFIc3EdwaQpF70kz3ozIrza5jn5dfHlev-tvLz6-n3_-bK0kspUSgnSSddbUbOO3XTCcKYcrztubGu5EYyzmnPatxwUgBK161xvasdsW_NaiXPy7tR7jPPvBTDpyaOFcTQB5gV1oxrFmBAZ5CfQxhkxQq-P0U8mPmhG9WpSD3o1qVeTmtY6m8yhN1v7cjOB-xvZ1GXg7QYYtGbsownW4yPHWddKzmTmPp44yC7uPUSN1kOw4HwEm7Sb_f_v-PRP3I4--LzxDh4Ah3mJIVvWTCPXVP9cf76-nHaUqqbtxB9DeKY2</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>Szeto, Cheuk-Chun, MD, FRCP</creator><creator>Kwan, Bonnie Ching-Ha, MBBS, MCP(UK)</creator><creator>Chow, Kai-Ming, MBChB, MRCP(UK)</creator><creator>Law, Man-Ching, BN, RN</creator><creator>Pang, Wing-Fai, MBChB, MRCP(UK)</creator><creator>Chung, Kwok-Yi, MBChB, MRCP(UK)</creator><creator>Leung, Chi-Bon, MBChB, FRCP(Edin)</creator><creator>Li, Philip Kam-Tao, MD, FRCP</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20091001</creationdate><title>Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment</title><author>Szeto, Cheuk-Chun, MD, FRCP ; Kwan, Bonnie Ching-Ha, MBBS, MCP(UK) ; Chow, Kai-Ming, MBChB, MRCP(UK) ; Law, Man-Ching, BN, RN ; Pang, Wing-Fai, MBChB, MRCP(UK) ; Chung, Kwok-Yi, MBChB, MRCP(UK) ; Leung, Chi-Bon, MBChB, FRCP(Edin) ; Li, Philip Kam-Tao, MD, FRCP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-55e5d5dfc34191b93a217d2492ac8c2a31214220f82e7ee734d9dfa4d1c842473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Abdomen</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>antibiotics</topic><topic>Biological and medical sciences</topic><topic>Cefazolin - therapeutic use</topic><topic>Ceftazidime - therapeutic use</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gentamicins - metabolism</topic><topic>Gentamicins - therapeutic use</topic><topic>Gram-Negative Bacterial Infections - drug therapy</topic><topic>Gram-Negative Bacterial Infections - microbiology</topic><topic>Gram-Positive Bacterial Infections - drug therapy</topic><topic>Gram-Positive Bacterial Infections - microbiology</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Netilmicin - therapeutic use</topic><topic>nosocomial infection</topic><topic>Other diseases. Semiology</topic><topic>Peritoneal Dialysis - adverse effects</topic><topic>Peritonitis - drug therapy</topic><topic>Peritonitis - etiology</topic><topic>Peritonitis - microbiology</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Renal failure</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szeto, Cheuk-Chun, MD, FRCP</creatorcontrib><creatorcontrib>Kwan, Bonnie Ching-Ha, MBBS, MCP(UK)</creatorcontrib><creatorcontrib>Chow, Kai-Ming, MBChB, MRCP(UK)</creatorcontrib><creatorcontrib>Law, Man-Ching, BN, RN</creatorcontrib><creatorcontrib>Pang, Wing-Fai, MBChB, MRCP(UK)</creatorcontrib><creatorcontrib>Chung, Kwok-Yi, MBChB, MRCP(UK)</creatorcontrib><creatorcontrib>Leung, Chi-Bon, MBChB, FRCP(Edin)</creatorcontrib><creatorcontrib>Li, Philip Kam-Tao, MD, FRCP</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szeto, Cheuk-Chun, MD, FRCP</au><au>Kwan, Bonnie Ching-Ha, MBBS, MCP(UK)</au><au>Chow, Kai-Ming, MBChB, MRCP(UK)</au><au>Law, Man-Ching, BN, RN</au><au>Pang, Wing-Fai, MBChB, MRCP(UK)</au><au>Chung, Kwok-Yi, MBChB, MRCP(UK)</au><au>Leung, Chi-Bon, MBChB, FRCP(Edin)</au><au>Li, Philip Kam-Tao, MD, FRCP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>54</volume><issue>4</issue><spage>702</spage><epage>710</epage><pages>702-710</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Background The clinical behavior and optimal treatment of relapsing and recurrent peritonitis episodes in patients undergoing long-term peritoneal dialysis are poorly understood. Study Design Retrospective study over 14 years. Setting &amp; Participants University dialysis unit; 157 relapsing episodes (same organism or culture-negative episode occurring within 4 weeks of completion of therapy for a prior episode), 125 recurrent episodes (different organism, occurs within 4 weeks of completion of therapy for a prior episode), and 764 control episodes (first peritonitis episode without relapse or recurrence). Predictors Exit-site infection, empirical antibiotics. Outcome Measures Primary response (resolution of abdominal pain, clearing of dialysate, and peritoneal dialysis effluent neutrophil count &lt; 100 cells/mL after 10 days of antibiotic therapy), complete cure (resolution by using antibiotics without relapse/recurrence), catheter removal (for any cause while on antibiotic therapy), and mortality. Results Compared with the control group, more relapsing episodes were caused by Pseudomonas species (16.6% versus 9.4%) and were culture negative (29.9% versus 16.4%); recurrent infections commonly were caused by Enterococcus species (3.2% versus 1.2%) or other Gram-negative organisms (27.2% versus 11.1%) or had mixed bacterial growth (17.6% versus 12.7%). There were significant differences in primary response, complete cure, and mortality rates among groups ( P &lt; 0.001 for all comparisons). Compared with the control and relapsing groups, post hoc analysis showed that the recurrent group had a significantly lower primary response rate (86.4%, 88.5%, and 71.2%, respectively), lower complete cure rate (72.3%, 62.4%, and 42.4%, respectively), and higher mortality rate (7.7%, 7.0%, and 20.8%, respectively). Limitations Retrospective analysis. Conclusion Relapsing and recurrent peritonitis episodes are caused by different spectra of bacteria and probably represent 2 distinct clinical entities. Recurrent peritonitis episodes had a worse prognosis than relapsing ones.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>19577352</pmid><doi>10.1053/j.ajkd.2009.04.032</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0272-6386
ispartof American journal of kidney diseases, 2009-10, Vol.54 (4), p.702-710
issn 0272-6386
1523-6838
language eng
recordid cdi_proquest_miscellaneous_67671133
source MEDLINE; Elsevier ScienceDirect Journals
subjects Abdomen
Adult
Aged
Anti-Bacterial Agents - therapeutic use
antibiotics
Biological and medical sciences
Cefazolin - therapeutic use
Ceftazidime - therapeutic use
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gentamicins - metabolism
Gentamicins - therapeutic use
Gram-Negative Bacterial Infections - drug therapy
Gram-Negative Bacterial Infections - microbiology
Gram-Positive Bacterial Infections - drug therapy
Gram-Positive Bacterial Infections - microbiology
Humans
Logistic Models
Male
Medical sciences
Middle Aged
Nephrology
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Netilmicin - therapeutic use
nosocomial infection
Other diseases. Semiology
Peritoneal Dialysis - adverse effects
Peritonitis - drug therapy
Peritonitis - etiology
Peritonitis - microbiology
Prognosis
Recurrence
Renal failure
Retrospective Studies
Risk Factors
Vancomycin - therapeutic use
title Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T23%3A04%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recurrent%20and%20Relapsing%20Peritonitis:%20Causative%20Organisms%20and%20Response%20to%20Treatment&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Szeto,%20Cheuk-Chun,%20MD,%20FRCP&rft.date=2009-10-01&rft.volume=54&rft.issue=4&rft.spage=702&rft.epage=710&rft.pages=702-710&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2009.04.032&rft_dat=%3Cproquest_cross%3E67671133%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67671133&rft_id=info:pmid/19577352&rft_els_id=1_s2_0_S0272638609007689&rfr_iscdi=true